Phico Therapeutics Ltd.
Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy.
Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy.
Phico Therapeutics Ltd. is a biotechnology company based in the United Kingdom, founded in 2000. The company is dedicated to tackling the pressing issue of antibiotic resistance with its innovative approach to engineered phage therapy. Their patented platform, SASPject™, utilizes an antibacterial protein, SASP, to inactivate bacterial DNA and effectively destroy multi-drug resistant bacteria, also known as "superbugs". This novel technology presents a promising solution to the challenge of antimicrobial resistance. Notably, Phico Therapeutics recently secured a significant £7.00M Venture Round investment on 11 May 2021, with the backing of Business Growth Fund. As the company continues to advance in the fields of Biopharma, Health Care, and Pharmaceuticals, their efforts are positioned to make a substantial impact in the fight against antibiotic resistance.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £7.00M | 1 | Business Growth Fund | 11 May 2021 |
| Grant | $5.30M | 1 |
|
19 Apr 2021 |
| Grant | £1.40M | 1 |
|
01 Aug 2018 |
| Venture Round | £3.60M | - | 20 Nov 2016 | |
| Venture Round | £2.30M | 2 |
|
24 Aug 2016 |
No recent news or press coverage available for Phico Therapeutics Ltd..
We care about your data, and we'd love to use cookies make your experience better.